SIMPOSIOS Y CONFERENCIAS

VHIO SPECIAL SYMPOSIUM:
Towards Predictive Cancer Models
26-27 May 2016
Barcelona  –  Spain

Supported by:

VHIO INTERNATIONAL SYMPOSIUM - Towards Predictive Cancer Models


Symposium Rationale from your Symposium Co-Chairs


In our collective onslaught against cancer the problems that we are all trying to solve are somewhat daunting, yet not insurmountable. While we believe solutions are within reach, they will need to be tackled collectively from different angles, employing diverse approaches, and conquered en force by all oncology professionals who see and understand things differently, from varying viewpoints.

In the current era of precision oncology, advances in translational cancer science and medicine are driven through multidisciplinarity. As we increasingly work in close connectivity whereby researchers and physician-scientists interact together on a daily basis, we have never before been better placed as a community to transform discovery into direct benefits for patients as quickly as possible. Fittingly, our Symposium will be inaugurated by perspectives presented by Josep Tabernero, Director of VHIO, on What Clinicians Expect from a Preclinical Cancer Model.

Conversation surrounding which predictive cancer models outperform others has been widely documented in the literature with each undergoing intense scrutiny. The predictive power of current preclinical models and the reliability of the data reported through recent studies are frequently called into question upon review of false positive results coupled with the compounds that, while showing efficacy in preclinical studies, ultimately fail in early phase trials.

According to a recent study published in eLife*, for example, colleagues from McGill University in Canada analyzed all the published animal studies of sunitinib and found that research reporting little or no anti-cancer effect were not published, leading to anticancer effects of the drug to be overestimated by as much as 45%. Whether this be the case or not, we do know that predicting which drug, or drug combination, will be the most effective based on the genetic makeup of a tumor remains a huge challenge, as does delivering on the promise of precision medicine for an increasing number of patients

We also know that it´s not a question about where to pin the best model medal. Each has its strengths, its limitations. By definition, no predictive model perfectly recapitulates human disease. While competition arguably spurs progress, our energies must focus on the collective end-goal of expanding and potentiating our current anti-cancer weaponry, as opposed to, discussion for discussion´s sake. The performance of a given model is a matter of extensive debate given the large number and range of different models employed in preclinical cancer research. Further, the requirements of any given model for cancer depends on which part of the disease is modeled, e.g. disease initiation, tumor growth, metastasis.

Just some of the must-have conversations during our Symposium will focus on future study design and how best to report, validate and share results so that we can ultimately build on the undeniable progress marked to-date by each and every model explored throughout our two-day symposium. We will be updated on the very latest research evidencing the ´tried, tested and validated´ of a variety of modeling systems and combined approaches across various tumor types as well as cutting-edge data coming from within the ´stable´ of novel contenders — organoids and PDX models. We will also discuss how data from preclinical models can be complementary to tumor genetic testing and thus push the boundaries of sequence-based approaches.

Our focus will center firmly on empowering current predictive cancer models by pooling knowledge, sharing perspectives and moving together to more swiftly, and more cost-effectively advance cancer precision medicine.

We look forward to welcoming you all to a meeting that will represent an important forward step in advancing prediction science against cancer,

Your Symposium Co-Chairs

Joaquín Arribas, Director of Preclinical Research, Vall d«Hebron Institute of Oncology (VHIO)

Laura Soucek, Principal Investigator, Mouse Models of Cancer Therapies Group, Vall d«Hebron Institute of Oncology (VHIO)

—-

*A meta-analysis of threats to valid clinical inference in preclinical research of sunitinib.Henderson VC1, Demo N1, Hakala A1, MacKinnon N1, Federico CA1, Fergusson D2, Kimmelman J1. Elife. 2015 Oct 13;4:e08351


Symposium Format


Our forthcoming Vall d´Hebron Institute of Oncology (VHIO) two-day Special Symposium on Towards Predictive Cancer Models, 26 – 27 May, 2016, Barcelona, Spain, has been expertly engineered to bring together an expert panel of internationally acclaimed speakers who will present and debate on and around the five especially selected sessions: 1) Cancer Immunology and Tumor Microenvironment, 2) New Prospectives, 3) Circumventing Therapy Resistance, 4) Redefining the Targets, and 5) New Opportunities from Human Tumor Samples: Explants, Organoids, and PDX.

Interspersed throughout the program we will also learn from, and interact with, our trio of keynote presenters, Lisa Coussens (USA), Scott Lowe (USA), and Mariano Barbacid (Spain), who will deliver the very latest discovery into complex interactions between immune system machinery and the dominant force in multi-drug resistance – the tumor microenvironment, crucial insights into cancer drivers provided by modelling cancer using non-germline GEMMS, as well as evidencing the necessity of modelling K-Ras tumors in mouse models as the test-bed for developing future therapies, respectively.

In addition to the main scientific program, we can also expect to discover yet more relevant and recent advances in predictive cancer science throughout the poster and networking sessions twinned throughout the two lunch breaks. Posters will be divided and displayed across these sessions with their respective author(s) present to discuss their data directly with us all. Following directly after lunch, prior to kicking off the next main symposium session, there will be three invited short talks selected from among the abstracts received.

In recognition of these contributions to our Symposium, prizes sponsored by Nature Reviews Cancer will be awarded to the presenters of the top two posters at the close of the meeting on Friday 27 May.

All registered participants are warmly invited to our Symposium Celebratory Cocktail. Commencing straight after the close of session on Thursday 26 May, we can look forward to our ´mix & mingle´ while enjoying an aperitif complete with traditional culinary delights.


Scientific Program


Vall d´Hebron Institute of Oncology (VHIO) Special Symposium:
Towards Predictive Cancer Models 
Barcelona, 26 – 27 May, 2016

PLEASE NOTE: our Scientific Program will be regularly updated. Please bookmark this page for all the latest information.

Thursday, May 26th

Time Event
8:45 – 9:00 Welcome Address:
Joaquín Arribas, Symposium Co-Chair
Esther Planas, Corporate Director of Finance and Resources, “la Caixa” Foundation (Spain)
Laura Soucek, Symposium Co-Chair
9:00
9:15
Jordi Rodón (Spain): What Clinicians Expect from a Preclinical Cancer Model
9:15
10:55
Session I (a): Cancer Immunology and Tumor Microenvironment
9:15
9:55
Keynote I: Lisa Coussens (USA): Immune Reprogramming in Solid Tumors as a Therapeutic Strategy
9:55
10:25
Victor Mulero (Spain): Modeling the Impact of Inflammation in Cancer Progression Using the Zebra Fish
10:25
10:55
Joaquin Arribas (Spain): Modeling Breast Cancer Therapy
11:00
11:30
Coffee Break
11:30
12:30
Session I (b): Cancer Immunology and Tumor Microenvironment
11:30
12:00
Gerard Evan (UK): Building Mouse Cancer Models Using Switchable Mouse Genetics to Model Cancer Evolution and Cancer Therapy
12:00
12:30
Marisol Soengas (Spain): Imaging and Targeting Premetastatic Niches in Melanoma
12:30
14:00
Session II: New Prospectives
12:30
13:00
Josep Villanueva (Spain): Diagnostic and Therapeutic implications of Unconventional Protein Secretion in Cancer
13:00
13:30
Marco Milan (Spain): The Other Side of Genomic Instability in Tumorigenesis: a Fly View
13:30
14:00
Joan Seoane (Spain):Intratumor Heterogeneity and Clonal Evolution in Glioblastoma
14:00
15:30
Lunch & Poster Session I
15:30
15:40
Short talk from posters #1
15:40
15:50
Short talk from posters #2
15:50
16:00
Short talk from posters #3
16:00
17:00
Session III: Circumventing Therapy Resistance
16:00
16:30
Violeta Serra (Spain): Circumventing Resistance to PARP Inhibitors
16:30
17:00
Jos Jonkers (The Netherlands): Genetic Dissection of Breast Cancer, Therapy Response and Resistance in Mouse Models
17:00
18:30
´Mix & Mingle´ Cocktail Reception
20:00
22:30
Speakers & Oral Poster Presenters´  Dinner

Friday, May 27th

Time Event
09:00
11:10
Session IV: Redefining the Targets
9:00
9:40
Keynote II: Scott Lowe (USA): Tumor Suppressor Networks
9:40
10:10
Louis Chesler (UK): Modeling and Targeting Pediatric Malignancies Using a Gene-Driven in-vivo Approach
10:10
10:40
Laura Soucek (Spain): Drugging the “Undruggable”: Inhibiting Myc to Combat Cancer
10:40
11:10
Maria Dominguez (Spain): A Drug Screen in a Drosophila Tumor Model Identifies Novel Anti-Cancer Drugs Effective in High-Risk Acute Lymphoblastic Leukemia
11:10
11:30
Coffee Break
11:30
13:30
Session V (a): New Opportunities from Human Tumor Samples: Explants, Organoids and PDX
11:30
12:00
Eduard Batlle (Spain): Model Systems to Study Colorectal Cancer Metastasis
12:00
12:30
Héctor G. Palmer (Spain): New Pre-Clinical Models to Study Target-Directed Drugs in Advance Colorectal Cancer
12:30
13:00
Herve Tiriac (USA): Accelerating Therapeutic Discovery with Human Pancreatic Organoids
13:00
13:30
Carlos Caldas (UK): Tumor Explants as a Pre-Clinical Drug Screening Platform in Human Breast Cancer
13:30
15:00
Lunch & Poster Session II
15:00
15:10
Short talk from posters #4
15:10
15:20
Short talk from posters #5
15:20
15:30
Short talk from posters #6
15:30
16:10
Keynote III: Mariano Barbacid (Spain): Modeling Human K-RAS Mutant Tumors in Mice: an Essential Tool for the Development of Future Therapies
16:10
17:10
Session V (b): New Opportunities from Human Tumor Samples: the Strengths of Explants, Organoids and PDX
16:10
16:40
Maurizio Scaltriti (USA): Therapeutic Strategies Tested and Validated in PDXs
16:40
17:10
Silvia Giordano (Italy): PDXs as a Tool to Design New Therapeutic Strategies for Gastric Cancer
17:10
17:25
Poster Prize
17:25
17:40
Co-Chairs Joaquín Arribas & Laura Soucek: Take Home Messages & Close


Registration & Abstract Submission


Registration

Registration covers access to all Scientific Sessions, the Program & Abstract Book, the Symposium ´Mix & Mingle´ Cocktail Reception (immediately following the close of the final session on Thursday 26 May 2016 as of 17:00h), coffee breaks and buffet lunches (poster and networking sessions).

REGISTRATION ONLINE IS NOW CLOSED.

IF YOU HAVE NOT YET REGISTERED AND WISH TO PARTICIPATE, YOU MAY REGISTERONSITE THROUGHOUT THE COURSE OF THE SYMPOSIUM.

http://web.omniprex.com/inscripciones/mkt_event/towards-predictive-cancer-models/

Early registration fees
(deadline 21/03/2016)
Regular registration fees
(deadline 23/05/2016)
Students
(incl. PhD Students)
100 EUR 150 EUR
Academic 150 EUR 200 EUR
Industry 200 EUR 300 EUR

PLEASE NOTE: registration does NOT include accommodation. Each participant must organize his/her own accommodation. For information about the official Symposium hotel and alternative accommodation situated close by to the symposium venue see below under ´Accommodation´.


Abstract Submission

ABSTRACT SUBMISSION IS NOW CLOSED.

Upon review by the Symposium Co-Chairs, abstracts will either be selected as posters or invited short talks scheduled within the main program directly following the two lunch and poster sessions. Topic scope will correspond to the main five symposium session themes.

PLEASE NOTE: Abstracts must not exceed max. 2550 characters (incl. spaces)

Abstract Submission is closed.  IMPORTANT: AUTHORS will be notified by email of acceptance as soon as possible as of 02 May 2016.

The best six abstracts will be selected to be presented in oral format; the remaining abstracts will be presented in poster format.
NATURE

As a reflection of the scientific programme of excellence, Nature Reviews Cancer is sponsor of our two poster prizes – to be announced and awarded by a special guest – to the presenters of the top two posters at the close of the meeting on 27 May.

PLEASE NOTE: the presentation of an abstract, either orally or as a poster, requires the registration of at least one of the authors to attend the Symposium.


Venue


PLEASE NOTE: due to an increased number of participants we will now be holding this Symposium in the Auditorium of the Pabellón Docente Building, the Vall d´Hebron University Hospital campus:

Pabellón Docente Auditorium

The Vall d´Hebron University Hospital

Natzaret Street with Arquitectura St.

08035 Barcelona, Spain


Dates for the Diary


Regular Registration Closes: 23 May 2016


Accommodation


PLEASE NOTE: registration does NOT include accommodation. Each participant must organize his/her own accommodation directly. For information about the official symposium hotel and alternative accommodation downtown, please click here. Should you have any queries regarding accommodation please contact our officially appointed scientific event logistics company OMNIPREX © INTERNATIONAL GROUP via email:VHIOsymposiumTPCM@omniprex.com.


Acknowledgement


On behalf of VHIO, the Symposium Co-Chairs gratefully thank the generous support received from the “La Caixa Foundation”:


Contact


For all queries concerning registration and/or abstract submission, and recommended options regarding accommodation please contact our officially appointed scientific event logistics company OMNIPREX © INTERNATIONAL GROUP:

Avda. Diagonal, 401 2º piso, 08008 Barcelona
Tel. +34 93 207 0478
Email: VHIOsymposiumTPCM@omniprex.com


VHIO/Weizmann Institute of Science Joint Conference on Cell Communication in Translational Research, 22 – 23 January, 2015, Rehovot, Israel

Sponsors:

  • Mr. David Gebler, Madrid, Spain
  • The Weizmann Institute of Science
  • The Weizmann Institute of Science Feinberg Graduate School
  • The Nancy & Stephen Grand Israel National Center for Personalized Medicine
  • The Vall d´Hebron Institute of Oncology (VHIO)

Please note: this is VHIO´s landing page for the forthcoming joint Weizmann Institute of Science – Vall d´Hebron Institute of Oncology Conference on Cell Communication in Translational Research, 22 – 23 January 2015, Rehovot, Israel. To visit the offical WIS-VHIO joint conference page please visit: http://wws.weizmann.ac.il/conferences/CCTR2015/


Conference Synopsis from the Co-Chairs


Cell communication is essential for life. Carried out in various ways, including through electromagnetic, chemical, and sensory signals, cellular communication underlies the development and activity of every cell. It is just beginning to be understood. However, what is well known is that cell communication can break down, resulting in various diseases and can also devolve into uncontrolled cell growth, often leading to cancer. Cancer can occur in many ways, but it always requires multiple signaling breakdowns. Often, cancer begins when a cell gains the ability to grow and divide even in the absence of a signal. Ordinarily this unregulated growth triggers a signal for self-destruction. But when the cell also loses the ability to respond to death signals, it divides out of control, forming a tumor. Later, cell communication events cause blood vessels to grow into the tumor, enabling it to grow larger. Additional signals allow the cancer to spread to other parts of the body. In cancer, the cellular communication systems provide potential targets for therapeutic intervention by “intercepting” signals and inhibiting the growth of tumors.

Basic research in biomedical sciences involves elucidating the mechanisms that drive diseases; clinical research addresses the complexity inherent in disease states, which is key to identifying the targets for pharmacological intervention. A combination of both these distinct approaches is needed for understanding human diseases, the majority of which are by nature multi-faceted and evolve over time. Translational research embodies such an amalgamation, by which lab science is translated to the intricacy of the ‘real’ world.

The goal of our VHIO/Weizmann Institute of Science Joint Conference on Cell Communication in Translational Research, 22 – 23 January, 2015, Rehovot, Israel, is to bring together researchers of these two intellectual powerhouses, as well as scientists from other institutions of excellence, in order to provide a platform for continuing dialogue and to subsequently launch productive collaborations addressing the questions and problems at the heart of the battle against cancer.

We look forward to warmly welcoming you all for this must-have conversation into the breakdown of cell communication, the consequential cancer growth and spread, and promising new therapeutic avenues against it.

Symposium Co-Chairs:

  • Irit Sagi, Weizmann Institute of Science, Rehovot, Israel
  • Joaquín Arribas, Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain


Scientific Program


Commencing with a welcome dinner on the evening of Wednesday, 21st January 2015 at the Weizmann Institute of Science, the official scientific program will run across one and a half days from Thursday 22nd January, 08:00 – 20:30h, including dinner following directly after the final session of the day, to Friday 23rd January, 08:30 – 12:30, with an optional informal, social opportunity thereafter to further enjoy the company of both speakers and participants alike.

Incorporating an outstanding panel of speakers, specially selected from among WIS and VHIO Faculty as well as other leading research institutes from Spain, the scientific program will be engineered to report on pioneering research into cancer molecular mechanisms and dedicated efforts towards precision cancer science and medicine:

22nd JANUARY 2015

08:00 – 08:45 Registration & Coffee

08:45 – 09:00 Welcome from the Co-Chairs Joaquín Arribas and Irit Sagi

09:00 – 10:25 SESSION I

09:00 – 09:35

Keynote: Yossi Yarden, Principal Investigator, Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel: It takes two to tango: HER2 and EGFR in cancer progression and therapy

09:35 – 10:00

Joaquín Arribas, ICREA Research Professor, Director of Preclinical Research, Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain: Targeting intercellular communication during breast cancer progression

10:00 – 10:25

Valery Krizhanovsky, Assistant Professor, Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel: Senescent cells communicate via intercellular protein transfer

10:25 – 10:45 Coffee Break

10:50 – 12:30 SESSION II

10:50 – 11:15

Héctor G. Palmer, Principal Investigator, Stem Cells & Cancer Group,Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain: New molecular insights in colorectal cancer metastasis and treatment

11:15 – 11:40

Irit Sagi, Principal Investigator, Department of Biological RegulationDean, Feinberg Graduate School, Weizmann Institute of Science, Rehovot, Israel: Cell-Communication combinatorial programs contributing to formation of cancer metastasis niche

11:40 – 12:05

Alicia Arroyo, Group Leader, Matrix Metalloproeinases in Angiogenesiand Inflammation, Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain: MT-MMPs: multi- faceted proteases in angiogenesis and inflammatory disease

12:05 – 12:30

Michal Neeman, Principal Investigator, Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel: Tumor-Stroma communication in ovarian carcinoma

12:30 – 13:30 Lunch

13:30 – 15:10 SESSION III

13:30 – 13:55

Ravid Straussman, Assistant Professor, Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel: The effects of crosstalk in the tumor microenvironment on chemoresistance

13:55 – 14:20

Joan Seoane, ICREA Research Professor, Director of Translational Research, Vall d´Hebron Institute of Oncology (VHIO), Barcelona Spain: Intratumor heterogeneity in brain tumors

14:20 – 14:45

Yardena Samuels, Principal Investigator, Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel: The genetics of melanoma: searching for new therapeutic targets

14:45 – 15:10

Berta Strulovici, Head of The Israel National Center for Personalized Medicine (INCPM), Weizmann Institute of Science, Rehovot, Israel:Enabling basic and clinical research with novel technology platforms

15:10 – 15:40 Coffee Break

15:40 – 17:00 SESSION IV

Selected talks, chosen out of abstract submitters:

15:40 – 15:55

Jonathan Whitfield, Staff Scientist, Mouse Models of Cancer Therapies Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain: Preclinical validation of Myc inhibition by a new generation of Omomyc-based inhibitors

16:00 – 16:20

Kim Pedersen, Post-Doctoral Fellow, Growth Factors Group, Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain: Pancreatic cancer heterogeneity and response to anti-MEK therapy

16:20 – 16:40

Dalit Barkan, Haifa University, Haifa, Israel: Integrin alpha V beta 3 expression in luminal breast cancer cells promotes their reversion to acinar-like structure in conjunction with their relevant microenvironment

16:40 – 17:00

Filip Bochner, Weizmann Institute of Science, Rehovot, Israel: A Novel Intravital Imaging Window for Longitudinal Microscopy of Mouse Ovary

17:00 – 18:25 Poster session and Student Flash Talks

18:25 – 20:25 Dinner

23rd JANUARY 2015

08:00 – 08:30 Gathering & Coffee

08:30 – 09:55 SESSION V

08:30 – 09:05

Keynote: Josep Tabernero, Director and Director of Clinical Research, Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain: Dissecting Colorectal Cancer in Multiple Targetable Subtypes

09:05 – 09:30

Diego Arango, Principal Investigator, CIBBIM – Nanomedicine Molecular Oncology, Vall d´Hebron Research Institute (VHIR), Barcelona Spain: RHOA inactivation enhances Wnt signalling and promotes colorectal cancer

09:30 – 09:55

Mosche Oren, Principal Investigator, Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel: p53 in the cross-talk between tumor and stroma

09:55 – 10:20 Coffee Break

10:20 – 11:50 SESSION VI

10:20 – 10:45

Idit Shachar, Weizmann Institute of Science, Rehovot, Israel: The molecular mechanism regulating the cross-talk between CLL cells and their microenvironment

10:45 – 11:25

Selected abstract talks:

10:45 – 11:00

Adi Sagiv, Weizmann Institute of Science, Rehovot, Israel: Mechanisms of Communciation between Senescent cells and NK cells

11:00 – 11:25

Oriol Arqués, Graduate Student, Stem Cells & Cancer Group, Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain: Tankyrase inhibition blocks Wnt/b-catenin pathway and reverts resistance to PI3K and AKT inhibitors in the treatment of colorectal cancer

—————–

11:25 – 11:50

Avigdor Scherz, Weizmann Institute of Science, Rehovot, Israel: Regressing cancer dissemination by local therapy and immune modulation – from bench to clinic

11:50 – 12:30 Closing Remarks: Joaquín Arribas and Irit Sagi

12:30             Trip to Jerusalem

13:30             Guided waling tour (in English) of Jerusalem

18:00             Expected arrival back at hotel in Rehovot


Abstract Submission & Registration


Abstract Submission and Registration are now closed. 


Contact


For any queries or questions please contact Amanda Wren directly: awren@vhio.net, Tel. +34 934893021, Mobile: +34 69520788.


FRITZ-BENDER-FOUNDATION/VHIO INTERNATIONAL SYMPOSIUM

17 Fritz Bender Foundation International Symposium-vhio

Please note: this is VHIO´s landing page for this forthcoming meeting. For all information including Abstract Submission, Registration and Accommodation visit the official symposium web page: www.vhiosymposium2013.com.


Symposium Synopsis

Marking the 17th international symposium in the annual series of prestigious meetings organized by the Fritz Bender Foundation, we are delighted to announce that Progress Towards Individualized Cancer Treatments will take place from 07 – 09 November 2013, hosted by VHIO.

FINAL CHANCE TO REGISTER BEFORE 05 NOVEMBER ONLINE AT:  www.vhiosymposium2013.com

Incorporating an outstanding panel of internationally renowned speakers, we can all look forward to two and a half days´ debate and exchange of the highest degree across the five main sessions: 1) Genetic Profiling of Patients, 2) Tumor Characterization, 3) Tumor-Host Relationships, 4) Therapeutic Targets I, and 5) Therapeutic Targets II.

In addition to the main scientific program, which will undoubtedly address some of the many remaining questions in our relentless efforts to change the face of cancer through precision cancer treatment and care, we can also expect to discover yet more relevant and recent advances within our field throughout the poster and networking sessions scheduled throughout the coffee and lunch breaks.

Some 60 posters will be divided and displayed across the first two days of the meeting, with their respective author(s) present to discuss the findings directly with us all. In recognition of these contributions, in collaboration with VHIO, both Nature Reviews Cancer and Nature Reviews Clinical Oncology have each sponsored a poster prize. To be judged by our Scientific Committee: Symposium Co-Chairs, Josep Tabernero, Director of VHIO and VHIO´s Clinical Research Program, Kurt S. Zaenker, the Fritz Bender Foundation and the University of Witten/Herdecke (Germany), Enrico Mihich, the Dana Farber Cancer Institute (USA), as well as Joaquín Arribas and Joan Seoane, Directors of VHIO´s Preclinical and Translational Research Programs, the prizes will be awarded to the presenters of the two top posters on the last day of the Symposium, Saturday 09 November.

All registered participants are also warmly invited to our Symposium Cocktail Reception. To commence straight after the close of sessions on Thursday 07 November, we will be enjoying an aperitif complete with traditional culinary delights and musical entertainment to be performed by one of our Symposium participants!

We look forward to joining you all for a meeting par excellence to both match and celebrate the successes of past Fritz Bender Foundation International Symposia.

Symposium Co-Chairs:

Josep Tabernero, Vall d´Hebron Institute of Oncology (Spain)

Kurt S. Zaenker, Fritz Bender Foundation & University of Witten/Herdecke (Germany)

Enrico Mihich, Dana Farber Cancer Institute (USA)

Symposium Co-Chairs:

  • Josep Tabernero, Vall d´Hebron Institute of Oncology (Spain)
  • Kurt S. Zaenker, Fritz Bender Foundation & University of Witten/Herdecke (Germany)
  • Erico Mihich, Dana Farber Cancer Institute (USA)


Scientific Program

PLEASE NOTE: The Scientific Program will be regularly updated. Please bookmark and visit  www.vhiosymposium2013.com for all the latest information.

Day 1: Thursday 07 November 2013

  • Welcome/Opening Address: 09:00 – 09:15
  • Enrico Mihich (USA) & Josep Tabernero (Spain)
  • Keynote Address: 09:15 – 10:00
  • Geoff Wahl (USA)

Dissecting Breast Cancer Through the Lens of Development; New Opportunities for Targeted Therapeutics

SESSION I: GENETIC PROFILING OF PATIENTS

Chair: Marco Pierotti (Italy)

10:00 – 13:15

1) Marco Pierotti (Italy) 10:00 – 10:40

Genetic Heterogeneity of Individuals at Increased Risk of Breast Cancer: Challenges for Clinical Exploitation

2) Hege E. Giercksky Russnes (Norway) 10:40 – 11:20

Inter- and Intra-Tumoral Heterogeneity of Breast Cancer; Diagnostic and Therapeutic Implications

Coffee/Posters 11:20 – 11: 35

3) Barrett Rollins (USA) 11:35 – 12:15

PROFILE: An Enterprise-Level Genomic Testing Program for Research and Clinical Care

SELECTED SHORT TALK: Thomas Dittmar (Germany) 12:15 – 12:35
Altered miRNA expression profile in hybrid cells derived from breast cancer cells and cells with stem cell properties 

Meet the Expert with Julio Celis (Denmark) 12:35 – 13:15

Coordination of Cancer Research in Europe: Challenges & Opportunities

LUNCH/POSTERS/NETWORKING 13:15 – 14:15

SESSION II: TUMOR CHARACTERIZATION

Chair: Joan Seoane (Spain)

14:15 – 18:10

1) Joan Seoane (Spain ) 14:15 – 14:55

Intra-Tumoral Heterogeneity in Brain Tumors

2) Manel Esteller (Spain) 14:55 – 15:35

Cancer PharmacoEpigentics: Genes & Drugs

3) Frank Thevenod (Germany) 15:35 – 16:15

Pituitary homeobox 2 (PITX2): A Novel Transcription Factor Mediating Drug Resistance in Cancer Cells by Upregulation of Multi-Drug Resistance P-Glycoprotein (ABCB1) 

Coffee/Posters 16:15 – 16:30

4) Maria Blasco (Spain) 16:30 – 17:10

Telomeres & Cancer

5) Carlos Caldas (UK) 17:10 – 17:50

The Genomic Characterization of Breast Cancer: Not One Disease but Ten Distinct Entities

6) Manuel Hidalgo (Spain) 17:50 – 18:30

Integrating PDX Models in Personalized Medicine Strategies     

7) Stefano Piccolo (Italy) 18:30 – 19:10

Beyond Hippo Signaing: Role of YAP & TAZ as Mecahnotransducers in Cancer

SELECTED SHORT TALK: Cristina Bernadó (Spain) 19:10 – 19:30
Mechanisms behind the Oncogene Induced Senescence (OIS) – Oncogene Induced Apoptosis (OIA) decision in cells expressing p95HER2 

SYMPOSIUM COCKTAIL/RECEPTION 19:30 –

Day 2: Friday 08 November 2013

SESSION III: TUMOR-HOST RELATIONSHIPS

Chair: Joaquín Arribas (Spain)

09:00 – 12:55

1) Olivera J. Finn (USA) 09:00 – 09:40

Therapeutic and Prophylactic Cancer Vaccines: the Original and Ultimate Personalized Cancer Treatment

2) Paola Allavena (Italy) 09:40 – 10:20

Targeting Tumor-Promoting Inflammation

Coffee/Posters 10:20 – 10:35

3) Soldano Ferrone (USA) 10:35 – 11:15

Antibody-Based Immunotherapy of Malignant Disease, Cancer Initiating Cells and Disease Recurrence

4) Federico Garrido (Spain) 11:15 – 11:55

MHC Antigens and Tumor Immune Escape

5) Joaquín Arribas (Spain) 11:55 – 12:35

Oncogene Induced Senescence During Breast Cancer Progression and Treatment

SELECTED SHORT TALK: Sandra Peiró 12:35 – 12:55
Regulation of Heterochromatin Transcription By Snail1/ LOXL2 During Epithelial to Mesenchymal Transition 

LUNCH/POSTERS/NETWORKING 12:55 – 14:00

SESSION IV: THERAPEUTIC TARGETS I

Chair: Antoni Ribas (USA)

14:00 – 17:55

1) Peter Jones (USA) 14:00 – 14:40

Targeting DNA Methylation Alterations in Cancer

2) Rafaella Giavazzi (Italy) 14:40 – 15:20

Targeting Angiogenesis in Ovarian Cancer

3) Levi Garraway (USA)  15:20 – 16:00

Systematic Studies of Cancer Genetics and Therapeutic Resistance

Coffee/Posters 16:00 – 16:15

4) Joe Gray (USA) 16:15 – 16:55

A Multiscale Architechtural Analysis of Cancer Genome Aberration Function

5) Michelle Garrett (UK) 16:55 – 17:35

Cancer Drug Discovery: From Therapeutic to Clinic

SELECTED SHORT TALK: Martin A. Rivas (Spain) 17:35 – 17:55
Sensitivity to combined MEK and mTORC1/2 inhibition in colorectal cancer is dictated by p53 mutational status

Meet the Expert with Gerard Evan (UK) 17:55 – 18:35

Choosing a Career in Cancer Research: Challenges and Rewards

Day 3 (half day): Saturday 09 November 2012

SESSION V: THERAPEUTIC TARGETS II

Chair: Josep Tabernero (Spain)

09:00 – 12:15

1) Neal Rosen (USA) 09:00 – 09:40

Oncogene Dependence Seed Back: Basic and Clinical Implications

2) Mina Bissell (USA) 09:40 – 10:20

Three Dimensional Models to Screen for Effective Drugs & for Understanding Where Dormant Cells Go in Breast Cancer & How Do They Wake Up to Metastasize

Coffee 10:20 – 10:35

4) Antoni Ribas (USA) 10:35 – 11:15

Building on the Success of BRAF Inhibitors & Immunotherapy for Melanoma

5) Josep Tabernero (Spain) 11:15 – 11:55

Dissecting CRC in Multiple, Targetable Diseases

SELECTED SHORT TALK: Cristina Puig-Saus (Spain) 11:55 – 12:15
iRGD (tumor-penetrating peptide)-modified oncolytic adenovirus shows enhanced antitumor efficacy

Summary     Kurt Zaenker (Germany) 12:15 – 13:00

POSTER PRIZE WINNERS ANNOUNCED AND AWARDED

Lunch & Departure


Registration & Abstract Submission

Please note: this is VHIO´s landing page for this forthcoming meeting. For all information including Abstract Submission, Registration, and Accommodation visit the official symposium web page: www.vhiosymposium2013.com.

We are delighted to announce that Nature Reviews Cancer and Nature Reviews Clinical Oncology will each sponsor a poster prize at the forthcoming VHIO-Fritz Bender Foundation joint International Symposium on Progress Towards Individualized Cancer Treatments, 07 – 09 November 2013, Barcelona, Spain. To be judged by our Scientific Committee, the prizes will be awarded to the presenters of the two top posters showcased during the meeting.

To view the Scientific Program, discover the many topics to be discussed and debated by our expert panel of internationally renowned speakers, and submit your abstract visit: http://www.vhiosymposium2013.com.

           Registration closes 05 November 2013

Registration covers access to all symposium sessions, the Program & Abstract Book, the symposium cocktail reception (immediately following close of final session on Thursday 07 November 2013 as of 19:00h), coffee breaks and buffet lunches (poster and networking sessions).

Registration fees 

Early registration fees(deadline 30/09/2013) Regular registration fee(deadline 05/11/2013)
Students  (including PhD Students) 160 EUR 200 EUR
Academic 200 EUR 250 EUR
Industry 240 EUR 300 EUR

Please note: registration does not include accommodation. Each participant must organize his/her own accommodation. For information about the official Symposium hotel and alternative accommodation situated close by to the symposium venue, click here, or visit: www.vhiosymposium2013.com.


Dates for the Diary & Symposium Venue

Final registration closes: 05 November 2013

Symposium Venue:

Pabellón Docente Auditorium

The Vall d´Hebron University Hospital

Natzaret Street with Arquitectura St.

08035 Barcelona, Spain


Accommodation

Please note: registration does not include accommodation. Each participant must organize his/her own accommodation. For information about the official Symposium hotel and alternative accommodation situated close by to the symposium venue, click here, or visit: www.vhiosymposium2013.com.


Contact

For all queries concerning registration and/or abstract submission, recommended options regarding accommodation,  please contact our officially appointed scientific event logistics company, OMINIPREX S.L. directly:

OMNIPREX© INTERNATIONAL GROUP